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Abstract
Background: Placental mRNA was detected in maternal whole blood, raising the possibility of using maternal blood for
noninvasive prenatal diagnosis. We investigated fetal mRNA detection in maternal whole blood and determined if it offered
advantages over maternal plasma analysis.
Methodology: The concentrations of placental expressed genes, CSH1, KISS1, PLAC4 and PLAC1 in plasma and whole blood
from healthy pregnant and non-pregnant individuals were compared by real-time quantitative reverse-transcriptase
polymerase chain reaction analysis. Their fetal specificity was investigated by comparing the transcript concentrations in
pre- and post-delivery samples and through SNP genotyping by matrix-assisted laser-desorption and ionization time-of-
flight mass spectrometry. The gene expression profiles of pregnant and non-pregnant whole blood were investigated by
microarray analysis. Upregulated genes in pregnant whole blood were selected for further quantitative analysis.
Principal Findings: The concentrations of the four transcripts were significantly higher in third trimester maternal whole
blood than corresponding plasma without significant correlations. KISS1, PLAC4 and PLAC1 were detected in non-pregnant
whole blood but not plasma. The transcripts remained detectable in some postpartum whole blood samples. The PLAC4
mRNA in maternal plasma showed fetal genotype while that in corresponding whole blood indicated both fetal and
maternal contributions. Microarray analysis revealed upregulation of genes involved in neutrophil functions in pregnant
whole blood including DEFA4, CEACAM8, OLFM4, ORM1, MMP8 and MPO. Though possibly pregnancy-related, they were not
pregnancy-specific as suggested by the lack of post-delivery reduction in concentrations.
Conclusions: Maternal plasma is preferred over maternal whole blood for placenta-derived fetal RNA detection. Most
studied ‘placental’ mRNA molecules in maternal whole blood were of maternal origin and might be derived from processes
such as ‘illegitimate transcription’.
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Introduction
The analysis of fetal nucleic acids in maternal plasma holds
much promise for noninvasive prenatal diagnosis [1–3]. Many
investigations conducted to date were based on the detection of Y
chromosomal sequences in maternal plasma [4], thus, limiting the
utility of such applications to pregnancies involving male fetuses
only. Circulating fetal mRNA analysis, on the other hand, offers a
means for noninvasive prenatal assessment that is applicable to
pregnancies regardless of the fetal gender [5–7].
Through the detection of the mRNA of placental expressed
hormones, namely chorionic somatomammotropin hormone 1 (placental
lactogen) (CSH1, NM_001317) and chorionic gonadotropin, beta
polypeptide (CGB, NM_000737), the placenta was shown to be a
source for fetal mRNA release into maternal plasma [5]. This
observation facilitated the development of a microarray-based
strategy to systematically identify placental expressed mRNA
markers that were detectable in maternal plasma [6]. Further-
more, aberrant concentrations of placental expressed mRNA
species have been shown to be associated with pregnancy
complications, such as the elevation of corticotropin releasing hormone
(CRH, NM_000756) mRNA in maternal plasma of preeclamptic
pregnancies [7,8]. In 2007, Lo et al. demonstrated that fetal
chromosomal aneuploidy, such as trisomy 21, can be detected
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5858non-invasively from maternal plasma analysis by RNA-single
nucleotide polymorphism (RNA-SNP) allelic ratio determination
[9]. These studies suggest that circulating placental mRNA
detection offers much opportunity for the development of
noninvasive prenatal diagnostic or assessment applications.
Besides maternal plasma, maternal whole blood has been
reported to be another medium for fetal mRNA detection [10–
14]. CSH1, CGB and placenta-specific 4 (PLAC4, NM_182832)
mRNA concentrations were reported to be much higher in
maternal whole blood than plasma [12,14]. Indeed, the total RNA
content of whole blood is higher than plasma. Hence, in this study,
we investigated the detection of fetal mRNA in maternal whole
blood and determined if it offered advantages over maternal
plasma analysis.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethics approval from the Joint
Chinese University of Hong Kong-New Territories East Cluster
Clinical Research Ethics Committee was obtained (CRE-
2005.131). All patients provided written informed consent for
the collection of samples and subsequent analysis.
Study design
Using real-time quantitative reverse-transcriptase polymerase
chain reaction (QRT-PCR), we first compared the concentrations
of four previously studied placental expressed transcripts, CSH1,
KiSS-1 metastasis-suppressor (KISS1, NM_002256), placenta-specific 1
(PLAC1, NM_021796) [5] and PLAC4 [9] in maternal plasma and
whole blood. Our previous microarray study [6] showed that these
transcripts had much higher expression in placental tissues than
blood cells. The relative placental-specificity of these transcripts
are also supported by data in the public database, SymAtlas
v1.2.4, Genomics Institute of the Novartis Research Foundation
(Figure S1, S2, S3) [15]. Figure S1, S2, S3 shows that those
transcripts are predominantly expressed in placental tissues as
compared with the many other human tissues assessed by gene
expression microarrays. We then determined the pregnancy-
specificity of CSH1, KISS1, PLAC1 and PLAC4 by assessing their
disappearance in post-delivery blood samples and detectability in
blood samples of non-pregnant females and males. We further
confirmed the fetal specificity of PLAC4 and chorionic somatomam-
motropin hormone-like 1 (CSHL1, NM_022579) mRNA by studying
their genotypes in maternal plasma and whole blood using the
RNA-SNP approach by matrix-assisted laser-desorption and
ionization time-of-flight mass spectrometry. CSHL1 is one of the
potentially pregnancy-specific placental expressed transcripts
identified in our previous microarray study [6]. Lastly, to exploit
if more pregnancy-related circulating mRNA markers could be
developed for maternal whole blood analysis, we mined for
candidates after performing gene expression microarray compar-
ison of whole blood samples from pregnant and non-pregnant
individuals.
Subjects and sample collection
Third trimester healthy women with singleton uncomplicated
pregnancies (gestational age range, 38–39 weeks) were recruited
with written informed consent from the Prince of Wales Hospital,
Hong Kong. 12 mL of peripheral blood was collected into EDTA
tubes before and at 24 hours after delivery. Placental tissues were
collected immediately after delivery. Age-matched healthy non-
pregnant individuals were recruited from the community.
General sample processing
Blood samples were processed within 6 hours. 300 mL whole
blood was added into 900 mL Trizol LS reagent (Invitrogen). The
remainder of the whole blood sample was processed as previously
reported for plasma and buffy coat [5,9,16]. All the processed
blood samples were stored at 280uC until RNA or DNA
extraction. Placental tissue samples were handled as per previous
studies [5,9].
RNA extraction
For every 1.8 mL of plasma-Trizol-LS mixture and 1.2 mL of
whole blood-Trizol-LS mixture, 200 mL and 240 mL of chloro-
form were added, respectively, and centrifuged at 12,000 g for
15 min at 4uC. The aqueous phase collected was mixed with 0.54
volume of 100% ethanol. All mixture from a single sample was
applied to a RNeasy minicolumn (Qiagen) and processed following
the manufacturer’s protocol. Total RNA was eluted with 48 mLo f
RNase-free water. Placental RNA was extracted as reported [5,9].
DNase I (Invitrogen) treatment was performed to remove genomic
DNA contamination.
DNA extraction
Maternal buffy coat and placental tissue DNA was extracted as
previously described [9].
Genes Investigated In This Study
Human genes: CSH1, chorionic somatomammotropin hormone 1
(placental lactogen) (NM_001317); KISS1, KiSS-1 metastasis-sup-
pressor (NM_002256); PLAC1, placenta-specific 1 (NM_021796);
PLAC4, placenta-specific 4 (NM_182832); CSHL1,c h o r i o n i cs o m a -
tomammotropin hormone-like 1 (NM_022579); DEFA4,d e f e n s i n ,
alpha 4, corticostatin (NM_001925); CEACAM8, carcinoembryonic
antigen-related cell adhesion molecule 8 (NM_001816); OLFM4,
olflactomedin 4 (NM_006418); FLCN, folliculin (NM_144606);
ORM1, orosomucoid 1 (NM_000607); MMP8, matrix metallopepti-
dase 8 (neutrophil collagenase) (NM_002424); MPO,m y e l o p e r o x i -
dase (NM_000250).
Real-Time QRT-PCR
All mRNA transcripts were quantified using one-step QRT-
PCR. Calibration curves were prepared by serial dilutions of
HPLC-purified single-stranded synthetic DNA oligonucleotides
(Proligos, Singapore) with the amplicon specified. The sequence
information of the primers, probes and calibrators as well as the
reaction conditions are summarized in Table S1. QRT-PCR was
set up as previously described [6,9].
RNA-SNP genotyping
Genotyping of PLAC4 SNP, rs8130833, and CSHL1 SNP,
rs2246207, was performed involving steps of reverse transcription
of RNA, PCR amplification, base extension and mass spectro-
metric analysis of the extension products [9]. DNA was extracted
from placental tissues and maternal buffy coat for determination of
the fetal and maternal genomic genotypes. The circulating PLAC4
and CSHL1 mRNA genotypes were then determined in maternal
plasma and whole blood samples and further compared with the
fetal and maternal genomic genotypes to confirm if they indeed
originated from the fetus.
Protocols for the PLAC4 SNP genotyping assay have been
described previously [9]. Procedures for CSHL1 w e r et h es a m ea s
PLAC4 except that 454 ng placental RNA, 2.5 ng whole blood RNA
or 48 mL plasma RNA was reverse transcribed at 60uC for 60 min
followed by 85uC for 5 min. Placental cDNA of 2.5 mL was added to
Maternal Blood Placental mRNA
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for plasma or whole blood cDNA. The PCR reaction mix was the
same as that for PLAC4 except 16HotStar Taq PCR buffer was used
for placental cDNA. The PCR was initiated at 95uC for 15 min,
followed by 45 cycles of denaturation at 95uC for 20 s, annealing at
65uC for 30 s and extension at 72uC for 1 min with final incubation
at 72uC for 3 min. 75 cycles were performed in the primer extension
reaction for CSHL1. Primer sequences and molecular weights for the
extension primer and extension products of each SNP allele are
shown in Tables S2 and S3.
Gene expression microarray analysis
From each of five third trimester pregnant women and five non-
pregnant healthy females, 5 mL of peripheral blood was collected
into PAXgene
TM blood RNA tubes (PreAnalytiX) with further
processing and RNA extraction according to manufacturer’s
instructions. DNase treatment was performed with RNase-Free
DNase Set (Qiagen). 7 mgo fe x t r a c t e dR N Af r o me a c hs a m p l ew a s
treated following the globin-reduction protocol recommended by
Affymetrix [17]. The globin-reduced RNA was labeled and
hybridized to the GeneChipH Human Genome U133A and
U133B Arrays (Affymetrix, Santa Clara, CA) according to
manufacturer’s instructions. After hybridization, each array chip
was washed, stained and scanned as reported [6]. The data were
analyzed with GeneSpring v 7.2 (Agilent Technologies, Palo Alto,
CA).
The microarray data in the. CEL format was imported and
normalized using the following steps in sequence: (1) raw data
processing by Robust Multi-chip Average, with GC-content
background correction (GC-RMA); (2) data transformation
whereby microarray data with values below 0.001 were set to
0.001; and (3) the signal intensity for each gene was divided by the
median of its measurements in all samples. After filtering the gene-
list with 70% confidence interval and non-parametric t-test
analysis (P=0.05), 2246 gene transcripts demonstrated differential
expression between pregnant and non-pregnant blood samples.
The gene list was further filtered by selecting transcripts with 1.5-
fold higher expression in the pregnant compared with non-
pregnant blood samples, and resulted in 247 gene transcripts. We
sorted these genes in descending order of the fold difference.
Statistics
Statistical analyses were performed using Sigma Stat (Systat).
Results
placental mRNA concentrations in third trimester
maternal plasma and whole blood
Whole blood and plasma samples from ten third trimester
pregnancies were analyzed. The median (range) concentrations for
CSH1, KISS1, PLAC4 and PLAC1 mRNA in whole blood were 90
673 (9 324–387 010), 14 712 (0–71 544), 344 330 (88 940–552
686) and 12 498 (3 250–54 328) copies/mL, respectively. The
median (range) concentrations for CSH1, KISS1, PLAC4 and
PLAC1 mRNA in plasma were 11 338 (1 771–27 754), 535 (0–2
283), 4 317 (2 779–10 737) and 498 (0–1 276) copies/mL,
respectively. The median concentrations of CSH1, KISS1, PLAC4
and PLAC1 mRNA were 8-fold (P=0.001, Mann-Whitney test),
27-fold (P=0.017, Mann-Whitney test), 80-fold (P,0.001, Mann-
Whitney test) and 25-fold (P,0.001, Mann-Whitney test) higher,
respectively, in whole blood than plasma. Using the Spearman
correlation test, no statistical significant correlation was observed
between the whole blood and plasma mRNA signals for CSH1
(R
2=0.045, P=0.583), KISS1 (R
2=0.003, P=0.365), PLAC4
(R
2=0.013, P=0.631), and PLAC1 (R
2=0.041, P=0.631).
Post-delivery clearance
Whole blood and plasma samples were also collected 24 hours
after delivery from the ten cases discussed above. The four
transcripts were no longer detectable in all postpartum plasma
samples. The plasma concentrations detected before and after
delivery were statistically significant for all transcripts (P,0.001,
Wilcoxon test). For the post-delivery whole blood samples, CSH1
and KISS1 mRNA became undetectable in 8 and 9 cases,
respectively. However, PLAC4 mRNA remained detectable in all
cases at a median concentration of 162 203 copies/mL. PLAC1
mRNA was detected in 7 post-delivery whole blood samples at a
median of 10 081 copies/mL (Figure 1). Using the Wilcoxon test,
the whole blood concentrations detected before and after delivery
were shown to be significantly different for CSH1 and KISS1
(P,0.001) but not for PLAC4 (P=0.160) and PLAC1 (P=0.105).
non-pregnant individuals
CSH1, KISS1, PLAC1 and PLAC4 mRNA were not detectable in
the plasma of 10 non-pregnant females and 10 males. Whole blood
samples from these 20 individuals showed absence of CSH1
mRNA. KISS1 mRNA was detected in whole blood of 2 each of
the non-pregnant females and males at 96 and 1 315 copies/mL in
the former group and 264 and 300 copies/mL in the males.
PLAC4 mRNA was detected in all 20 whole blood samples with
median concentrations of 244 498 copies/mL and 592 372
copies/mL, respectively, in non-pregnant females and males.
PLAC1 mRNA could be detected in whole blood of 9 non-
pregnant females and 8 males at median concentrations of 12 024
copies/mL and 7 959 copies/mL, respectively. These concentra-
tions were not significantly different from that of the third
trimester whole blood samples for PLAC4 (P=0.065, Kruskal-
Wallis one way analysis of variance (Kruskal-Wallis ANOVA) test)
and PLAC1 (P=0.368, Kruskal-Wallis ANOVA test) (Figure 2).
Genotyping of PLAC4 and CSHL1
Third trimester placental tissues, maternal whole blood, buffy coat
and plasma samples were collected. We aimed to compare the
genotypes of the placental mRNA transcripts, PLAC4 and CSHL1,i n
maternal plasma and whole blood with the genomic genotypes of the
fetal-maternal pairs to confirm if the circulating transcripts were truly
of fetal origin. PLAC4has a SNP,rs8130833, withinthe coding region
[9]. CSHL1 was targeted because it demonstrated high placental
tissue expression at similar levels like CSH1 which was highly
homologous with other genes of the growth hormone cluster and that
a target-specific RNA-SNP assay could not be developed [6].
The fetal and maternal genotypes for each pregnancy were first
determined using placental tissue and maternal buffy coat DNA.
Though nucleated fetal cells may be present at a density of 1 to 6 cells
per milliliter of maternal blood in the samples [18,19], such a level of
‘‘contaminant’’ would unlikely affect the predominant maternal
genotype detected in maternal blood cells. Cases where the fetal and
maternal genotypes differed were considered as informative and
included 7 out of 28 cases for PLAC4 and 11 out of 50 cases for
CSHL1.T h ePLAC4 and CSHL1 mRNA genotypes were then
determined in maternal plasma and wholeblood RNA samples of the
informative pregnancies. Representative mass spectra for PLAC4 and
CSHL1 RNA-SNP genotyping are shown in Figures S4 and S5. The
genotyping data of all informative cases are summarized in Table 1.
For PLAC4 mRNA, the genotype in maternal plasma corresponded
to that of the fetus while the genotype in whole blood was always
heterozygous indicating both fetal and maternal contributions. For
Maternal Blood Placental mRNA
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samples were identical to the fetus.
Gene expression profile comparison between pregnant
and non-pregnant female blood samples
The gene expression profiles of five third trimester and five non-
pregnant female whole blood samples were compared using
GeneSpringH v 7.2, (Agilent Technologies) software. The data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus [20] and are accessible through GEO Series
accession number GSE14771 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token=hfavtosmyeoygzq&acc=GSE14771). The fi-
nal gene list was generated by selecting transcripts with 1.5-fold
higher expression in the pregnant than non-pregnant blood samples
and resulted in 247 gene transcripts. We sorted these genes in
descending order of the fold difference (Table 2). Twenty of the top
Figure 1. Concentrations of placenta-derived mRNA in pre- and 24-hour-post delivery maternal whole blood. Scatter plots of (A) CSH1
(B) KISS1 (C) PLAC4 (D) PLAC1 mRNA. Corresponding samples from each individual are connected by a line.
doi:10.1371/journal.pone.0005858.g001
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and more specifically the functions of neutrophils (13/25) (Table 2).
However, placental expressed transcripts previously identified,
namely CSH1, CSHL1, KISS1, PLAC4 and PLAC1 were not present
on the list. Defensin, alpha 4, corticostatin (DEFA4, NM_001925),
carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8,
NM_001816),olflactomedin4 (OLFM4, NM_006418),folliculin(FLCN,
NM_144606), orosomucoid 1 (ORM1, NM_000607), matrix metallopep-
tidase 8 (neutrophil collagenase) (MMP8, NM_002424) and myeloperox-
idase (MPO, NM_000250) which represented transcripts with large,
Figure 2. Concentrations of placenta-derived mRNA in third trimester pregnant and non-pregnant female and male whole blood.
Box plots of (A) CSH1 (B) KISS1 (C) PLAC4 (D) PLAC1 mRNA. The line inside each box denotes the median. The lower and upper limits denote the 25th
and 75th percentiles, respectively. The lower and upper whiskers denote the 10th and 90th percentiles, respectively. Filled circles denote the outliers.
Asterisks denote all the data below detection limit of 8 copies per reaction.
doi:10.1371/journal.pone.0005858.g002
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non-pregnant blood were further analyzed (Table 2).
Quantification of the whole blood mRNA markers in third
trimester whole blood and placental tissues. We assessed if
the pregnancy-related whole blood mRNA transcripts were likely
to have originated from the placenta. Placental tissue and whole
blood samples were collected from ten pregnancies. The median
mRNA concentrations for DEFA4, CEACAM8, OLFM4, FLCN,
ORM1, MMP8 and MPO were 0, 0, 3, 60, 0, 3 and 2 copies per
nanogram placental RNA, respectively. Correspondingly, the
median concentrations in whole blood samples were 125, 1181,
781, 207, 338, 386 and 200 copies per nanogram whole blood
RNA in third trimester cases.
Concentrations of whole blood mRNA markers in pre-
and post-delivery maternal whole blood. After normalizing
with GAPDH to adjust for the leukocyte concentration in whole
blood, a statistically significant decreasing trend was observed in
the post-delivery maternal blood samples for transcripts DEFA4,
CEACAM8, OLFM4 and MMP8 comparing with the
corresponding pre-delivery blood samples according to the
Wilcoxon test (P,0.05). No significant difference was observed
for FLCN (P=1.00), ORM1 (P=0.63) and MPO (P=0.06)
(Figure 3).
Concentrations of whole blood mRNA markers in third
trimester and non-pregnant whole blood. When comparing
the absolute concentrations of DEFA4, CEACAM8, OLFM4, FLCN,
ORM1, MMP8 and MPO mRNA in whole blood samples from
third trimester pregnant, non-pregnant female and male, statistical
significant differences were observed in the markers (P,0.001,
Kruskal-Wallis ANOVA test) except FLCN (P=0.231, Kruskal-
Wallis ANOVA test) (Figure 4).
However, after normalization with GAPDH to adjust for the
leukocyte concentration in whole blood (data not shown),
significant differences among third trimester pregnant, non-
pregnant female and male whole blood were only found for
transcripts OLFM4 and FLCN (P,0.05, Kruskal-Wallis ANOVA
test).
Discussion
For decades, to develop noninvasive prenatal diagnosis,
investigators have focused on the search for intact fetal cells in
maternal blood [21,22]. However, the rarity of such cells has
hindered their robust identification in maternal blood [23]. The
discoveries of cell-free fetal DNA [4] and later placental mRNA
[5] in maternal plasma have offered new opportunities for the
development of noninvasive prenatal diagnosis [9]. More recently,
placental expressed and pregnancy-associated transcripts have
been reported to be detectable in maternal whole blood [10–14].
As the RNA yield in whole blood far exceeds that of plasma, we
explored in this study if maternal whole blood might represent a
better specimen type for the detection of fetal specific placenta-
derived mRNA.
We confirmed that placental expressed mRNA concentrations
in third trimester whole blood were indeed higher than that in
plasma for CSH1, KISS1, PLAC4 and PLAC1. The observation was
consistent with previous reports [12,14]. While the four transcripts
were not detectable in all post-delivery maternal plasma samples,
there were no significant reductions in PLAC4 and PLAC1 mRNA
concentrations in maternal whole blood samples collected 24 h
after delivery. In non-pregnant females and males, all four
placental transcripts were absent in plasma but PLAC4 and PLAC1
could be detected in the whole blood of both non-pregnant females
and males. These data suggested that the PLAC4 and PLAC1
mRNA in whole blood could be derived from tissues or organs
other than the placenta. This could also explain the lack of
clearance of PLAC4 and PLAC1 mRNA from maternal whole
blood after delivery. This is further supported by the lack of
statistical significant correlations between the whole blood and
plasma signals for CSH1, KISS1, PLAC4 and PLAC1 suggesting that
the mRNA species detected in the two specimen types possibly
have originated from different tissue sources.
It is believed that fetal or placental RNA is released into the
maternal circulation due to apoptosis of the trophoblast cells
[5,24]. If our targeted RNA transcripts were indeed placenta-
derived, they should carry the same genotype as the fetus. The
concordance between the placental tissue and plasma RNA-SNP
genotyping results for PLAC4 and CSHL1 confirmed the fetal
origin of such mRNA molecules in maternal plasma. As for
maternal whole blood mRNA, the CSHL1 genotype was
concordant with that of the fetus while the PLAC4 genotype was
always heterozygous even when the fetus was homozygous (cases
1160 and 1359 in Table 1). This latter observation suggests that
there is maternal contribution to the detectable PLAC4 mRNA in
maternal whole blood. This finding confirms those reported by Go
et al [25]. As can be appreciated from Table 1, pregnancies
involving a homozygous fetus but a heterozygous mother (cases
1160 and 1359) are more useful for confirming the fetal specificity
(i.e. absence of maternal transcript contamination) of the targeted
transcript. The presence of a fetal-specific allele in maternal
plasma (e.g. G-allele in case 668) merely suggests the existence of
fetal contribution to the mRNA pool but does not indicate that
there is no maternal transcript contamination. Yet, it is the
absence of the maternal specific allele (e.g. G-allele in case 1160)
that confirms the fetal-specificity of the transcript.
Table 1. PLAC4 and CSHL1 RNA-SNP genotyping in third
trimester maternal plasma and whole blood.
Sample No. DNA Genotype RNA-SNP Genotype
Fetus Mother Plasma
Whole
Blood
PLAC4 668 AG AA AG AG
696 AG AA AG AG
770 AG AA AG AG
774 AG GG AG AG
917 AG AA AG AG
1 1 6 0A AA GA AA G
1 3 5 9A AA GA AA G
CSHL1 1 1 7 2C CC TC CC C
2 4 3 2C CC TC CC C
137 CT CC CT CT
140 CT CC CT CT
846 CT CC CT CT
847 CT TT CT CT
929 CT CC CT CT
2 4 3 7C TT TC TC T
2 4 5 1C TT TC TC T
2 4 6 8C TT TC TC T
2 4 1 7T TC TT TT T
doi:10.1371/journal.pone.0005858.t001
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be pregnancy-specific in both plasma and whole blood. On the
contrary, PLAC4 and PLAC1 are pregnancy-specific only in plasma
but not whole blood which has both fetal and maternal
contributions. Thus, it is not surprising that Banzola et al reported
a lack of quantitative difference in whole blood PLAC4 (located on
chromosome 21) mRNA between euploid and trisomy 21
pregnancies [14]. Our data showed that there was no statistical
significant difference in whole blood PLAC4 mRNA concentra-
tions even between pregnant and non-pregnant individuals. One
possible explanation of the maternal contribution to these
apparently ‘‘placenta-derived’’ transcripts in whole blood may be
related to the phenomenon of illegitimate expression that
lymphocytes had been shown to express transcripts irrelevant to
their functions [26–28]. Microarray analyses do not reveal these
expression profiles because microarray expression data are often
presented in a relative scale where the extremely low abundance
signals will be dwarfed by the high abundance signals. These low
abundance signals in blood cells may become a significant
contaminant in terms of absolute quantities when whole blood is
the biological sample analyzed.
Nonetheless, CSH1, CSHL1 and KISS1 appeared to be
pregnancy-specific in whole blood. Thus, we systematically
investigated if other pregnancy-specific whole blood mRNA
markers could be developed based on microarray comparison of
pregnant and non-pregnant whole blood samples. We found 247
genes which showed at least 1.5-fold elevation in the former than
the latter group. Thirteen of the top 25 transcripts on the list were
related to blood cell functions, especially that of neutrophils. This
is not surprising as pregnancy has been reported to induce
inflammatory change in peripheral blood and neutrophils are
major contributors to inflammation [29,30]. Unexpectedly, none
Table 2. List of genes more highly expressed in whole blood of third trimester pregnant female than non-pregnant female.
aTranscripts
aGene Name Probe Set ID
Genbank
Accession No.
bFold
Change
Expression
in Pregnant
Blood
Expression in
Non-pregnant
Blood
defensin, alpha 4, corticostatin DEFA4 207269_at NM_001925 26.5 212.1 8.0
carcinoembryonic antigen-related cell
adhesion molecule 8
CEACAM8 206676_at M33326 22.9 373.9 16.3
Transcribed sequences 231688_at AW337833 21.4 206.2 9.6
lactotransferrin LTF 202018_s_at NM_002343 17.2 541.1 31.5
lipocalin 2 LCN2 212531_at NM_005564 17.1 344.1 20.1
olfactomedin 4 OLFM4 212768_s_at AL390736 15.6 141.3 9.1
defensin, alpha 1, myeloid-related sequence DEFA1 205033_s_at NM_004084 14.0 12060.0 864.5
cathelicidin antimicrobial peptide CAMP 210244_at U19970 13.7 531.9 38.8
cysteine-rich secretory protein 3 CRISP3 207802_at NM_006061 12.2 80.7 6.6
folliculin FLCN 235250_at AA992036 6.2 43.9 7.0
chitinase 3-like 1 CHI3L1 209396_s_at M80927 5.5 126.1 23.1
orosomucoid 1 ORM1 205041_s_at NM_000607 4.6 16.1 3.5
polycythemia rubra vera 1 PRV1 219669_at NM_020406 4.5 115.8 25.7
annexin A3 ANXA3 209369_at M63310 3.8 275.8 73.0
POU domain, class 6, transcription factor 1 POU6F1 216332_at L14482 3.7 39.2 10.5
transcobalamin I TCN1 205513_at NM_001062 3.7 87.9 23.8
carcinoembryonic antigen-related cell adhesion
molecule 6
CEACAM6 211657_at M18728 3.6 112.3 31.2
orosomucoid 2 ORM2 205040_at NM_000607 3.6 67.9 19.1
thyroglobulin TG 214977_at AK023852 3.3 18.8 5.7
T-cell receptor interacting molecule TRIM 217147_s_at AJ240085 3.1 183.1 58.5
matrix metalloproteinase 8 MMP8 207329_at NM_002424 3.1 23.9 7.7
S100 calcium binding protein A12 S100A12 205863_at NM_005621 3.0 2963.0 982.4
hemogen HEMGN 223669_at AF130060 3.0 593.0 196.9
S100 calcium binding protein P S100P 204351_at NM_005980 3.0 1576.0 530.5
matrix metalloproteinase 9 MMP9 203936_s_at NM_004994 2.8 428.2 155.7
A A AAA A A
neural proliferation, differentiation and control, 1 NPDC1 218086_at NM_015392 1.5 29.9 19.6
motile sperm domain containing 2 MOSPD2 221895_at AW469184 1.5 118.2 77.4
myeloperoxidase MPO 203949_at NM_000250 1.5 8.5 5.6
LOC401505 LOC401505 225036_at BF969806 1.5 89.7 58.8
aBold and italic fonts indicate the whole blood markers selected for QRT-PCR analysis.
bFold change is the fold difference in expression level between the pregnant and non-pregnant blood samples according to the microarray data.
doi:10.1371/journal.pone.0005858.t002
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PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5858of the previously studied placenta-derived transcripts, CSH1,
KISS1, PLAC4 and PLAC1, appeared on the gene list. This was also
the case as reported by Maron et al [13]. According to our QRT-
PCR data on the pregnancy-related whole blood markers such as
DEFA4, the median expression levels of these genes were much
higher than that of the placenta-derived transcripts in whole blood
(Figures 2 and 4). Therefore, it is possible that CSH1, CSHL1 and
KISS1 were ranked much lower than 247. Furthermore, as PLAC4
and PLAC1 were readily detectable in both pregnant and non-
pregnant whole blood and possibly without the 1.5-fold threshold
difference in expression, they would not have appeared on the
sorted gene list.
We have validated the pregnancy-specificity of 7 transcripts
with differences in expression between pregnant and non-pregnant
whole blood as determined by the microarray analysis. DEFA4 is
involved in host defense and found in neutrophils [31]. CEACAM8
is expressed only in neutrophils and eosinophils in humans with
undetermined function [32]. OLFM4 is previously recognized as
human granulocyte colony stimulating factor stimulated clone-1
with high expression in cancerous tissues [33]. FLCN is speculated
to be a tumor suppressor gene with unclear function [34]. ORM1
encodes a key acute phase plasma protein [35]. During pregnancy,
ORM1 is suggested to be involved in the maintenance of
homeostasis between maternal and fetal systems within the
chorioallantoic placenta [36]. MMP8 is expressed in diverse cell
types including neutrophils, macrophages, T cells, epithelial cells
and endothelial cells in inflammatory conditions [37,38]. MMP8
was also detected in the chorion during labor and was proposed to
be a predictive marker for preterm delivery [39,40]. MPO is a
heme protein primarily hosted in human polymorphonuclear
neutrophils [41]. During pregnancy, MPO was observed on the
surface of neutrophils [42].
Our QRT-PCR validation of the whole blood markers showed
a statistically significant difference between the expression levels
among third trimester pregnant, non-pregnant female and male
individuals for OLFM4 and FLCN only after normalization with
the corresponding GAPDH data. All markers, except FLCN, were
related to the hematopoietic system, especially the neutrophils. It
has also been reported that the total leukocyte count would rise
during pregnancy with neutrophils accounting for most of the
increased leukocyte count [43,44]. Hence, the increased expres-
sion level observed from the microarray data was probably due to
the augmented leukocyte number instead of the transcript
expression level in the cells. This may also explain why we found
a significant difference in concentrations of those transcripts only
when directly comparing the pregnant and non-pregnant whole
blood samples but not after GAPDH normalization.
The whole blood microarray study identified transcripts whose
functions were related to the physiological changes of pregnancy.
However, their presence in non-pregnant whole blood and lack of
clearance after pregnancy suggested that they werenot ‘‘pregnancy-
specific’’ markers, albeit being ‘‘pregnancy-related’’. As they were
also detectable in blood of non-pregnant individuals, they were
therefore not fetal-specific either. Concluding from all the data in
this study, it appears that placenta-derived fetal-specific transcripts
can be more readily identified from maternal plasma than whole
blood. While some transcripts are fetal-specific in maternal whole
blood,e.g. CSHL1,duecare isneededtovalidate eachnewpotential
whole blood transcript that is meant to be used as a circulating fetal
RNA marker. Illegitimate expression by maternal blood cells would
need to be excluded before adopting such a marker.
Supporting Information
Figure S1 Bar-charts adopted from Human GeneAtlas GNF1H
showing expression of (A) CSH1 (208356_x_at) and (B) CSHL1
(205958_x_at) in different human tissues. (http://symatlas.gnf.
org/SymAtlas)
Found at: doi:10.1371/journal.pone.0005858.s001 (2.28 MB TIF)
Figure S2 Bar-charts adopted from Human GeneAtlas GNF1H
showing expression of KISS1 (205563_at) in different human
tissues. (http://symatlas.gnf.org/SymAtlas)
Found at: doi:10.1371/journal.pone.0005858.s002 (0.17 MB TIF)
Figure S3 Bar-charts adopted from Human GeneAtlas GNF1H
showing expression of (A) PLAC4 (214750_at) and (B) PLAC1
(219702_at) in different human tissues. (http://symatlas.gnf.org/
SymAtlas)
Found at: doi:10.1371/journal.pone.0005858.s003 (2.60 MB TIF)
Figure S4 Mass spectra showing PLAC4 RNA-SNP genotypes
of placenta, third trimester maternal plasma and whole blood
samples. (A) a homozygous placental RNA sample showing a
single peak A with unextended primers (UEP). (B) third trimester
maternal plasma RNA showing a single peak A as the placental
RNA sample. (C) third trimester maternal whole blood RNA
showing a peak A and a minor peak G as indicated by the arrow.
Found at: doi:10.1371/journal.pone.0005858.s004 (1.09 MB TIF)
Figure S5 Mass spectra showing CSHL1 RNA-SNP genotypes
of placenta, third trimester maternal plasma and whole blood
samples. (A) a heterozygous placental RNA sample showing 2
peaks, allele C and allele T with unextended primers (UEP). (B)
third trimester maternal plasma RNA also showing 2 peaks as the
placental RNA sample. (C) third trimester maternal whole blood
RNA showing both peaks of allele C and allele T.
Found at: doi:10.1371/journal.pone.0005858.s005 (1.07 MB TIF)
Table S1 Primer, probe and calibrator sequences and reaction
conditions for quantitative real-time RT-PCR assays.
Found at: doi:10.1371/journal.pone.0005858.s006 (0.08 MB
DOC)
Table S2 Primer sequences for reverse transcription and PCR
amplification of the PLAC4 and CSHL1 SNP.
Found at: doi:10.1371/journal.pone.0005858.s007 (0.03 MB
DOC)
Table S3 Sequences and molecular weights of the extension
primer and the expected extension products for each of the alleles
of the PLAC4 and CSHL1 SNPs.
Found at: doi:10.1371/journal.pone.0005858.s008 (0.03 MB
DOC)
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Figure 3. Quantitative analysis of identified whole blood mRNA markers in pre- and 24-hour-post-delivery maternal whole blood. (A)
DEFA4. (B) CEACAM8.( C )OLFM4. (D) FLCN.( E )ORM1.( F )MMP8. (G) MPO mRNA. Corresponding samples from each individual are connected by a line.
doi:10.1371/journal.pone.0005858.g003
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Figure 4. Concentrations of identified whole blood mRNA in third trimester pregnant and non-pregnant whole blood. Box plots of (A)
DEFA4 (B) CEACAM8 (C) OLFM4 (D) FLCN (E) ORM1 (F) MMP8 (G) MPO mRNA. The line inside each box denotes the median. The lower and upper limits
denote the 25th and 75th percentiles, respectively. The lower and upper whiskers denote the 10th and 90th percentiles, respectively. Filled circles
denote the outliers. Asterisks indicate the groups with significant differences in mRNA concentrations of the marker (P,0.05, Kruskal-Wallis test
followed by pairwise comparison using the Student-Neuman-Keuls test).
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